Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 14/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 14/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 10/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 10/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796165 | 0.82 | KCNQ3 (0.44) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL7662714 | 0.81 | RRM2 (0.44) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL9220618 | 0.81 | STK17A (0.44) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL19796124 | 0.79 | MAPT (0.46) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL25191294 | 0.79 | KCNQ3 (0.50) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL7664958 | 0.78 | RRM2 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL12841596 | 0.78 | KCNQ3 (0.41) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL9218436 | 0.78 | STK17A (0.51) | — | |
| SCHEMBL18779716 | 0.77 | KCNH3 (0.40) | ALDH1A1KDM4EGAAKCNH3POLB | |
| SCHEMBL25687977 | 0.77 | FDFT1 (0.45) | ALDH1A1KDM4EGAAKCNH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3459953-B1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-30 | — | — | EP | disclosed |
| CN-109153681-B | Novel 5H-pyrrolo [2,3-d ] pyrimidin-6 (7H) -one derivatives | 大鹏药品工业株式会社 | 2021-06-04 | — | — | CN | disclosed |
| US-20190292190-A1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-09-26 | — | — | US | disclosed |
| EP-3459953-A1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083391-A1 | TRICYCLIC PIPERAZINE DERIVATIVE | PDE3A, PDE5A, PDE2A | KCNQ3 3994/4885KCNQ2 3626/4885KCNE1 2797/4885 |
| US-20190292190-A1 | NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE | RPS6KA1, RPS6KA3, MAPK9 | KCNQ3 4369/4885KCNQ2 4303/4885KCNE1 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.